Clearside biomedical announces successful end-of-phase 2 meeting with the fda and alignment on phase 3 plans for suprachoroidal cls-ax in wet amd

- cls-ax phase 3 program designed to maximize commercial potential in wet amd - - flexible dosing and extended duration would be important differentiators from existing approved therapies and other tyrosine kinase inhibitors in development - alpharetta, ga., march 06, 2025 (globe newswire) -- clearside biomedical, inc. (nasdaq: clsd) (“clearside” or the “company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (scs®), announced today the receipt of the formal meeting minutes from its recent end-of-phase 2 meeting with the u.s. food and drug administration (fda) relating to cls-ax (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet amd).
CLS Ratings Summary
CLS Quant Ranking